BIOG-B BioGaia AB (publ)

12.38USD125.80 SEK · STO+0.16%Mkt Cap: 1.25B USDP/E: 32.51

BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, a…

Institutional holders10 on file

Key Statistics

Company
Market Cap1.25B USD
Enterprise Value1.20B USD
Revenue (TTM)162.84M USD
Gross Profit111.09M USD
Net Income (TTM)32.75M USD
Revenue/Share1.61 USD
Last Price12.38 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees251
CountrySE
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINSE0017769995
Valuation
P/E (Trailing)32.51
P/E (Forward)29.05
PEG—
EV/EBITDA25.23
EV/Revenue7.38
P/S7.69
P/B10.42
EPS (TTM)0.38 USD
EPS (Forward)0.43 USD
52W Range
9.46974% of range13.42
52W High13.42 USD
52W Low9.469 USD
Profitability
Gross Margin73.37%
Oper. Margin28.23%
EBITDA Margin29.24%
Profit Margin21.63%
ROE25.32%
ROA20.83%
ROIC—
ROCE32.31%
Growth
Revenue Growth22.60%
Earnings Growth67.60%
Cash Flow & Leverage
Operating CF30.18M USD
CapEx (TTM)354.25K USD
FCF Margin10.18%
FCF Yield1.32%
Net Debt-51.01M USD
Net Debt/EBITDA-1.07
Net Debt/FCF-3.08
Balance Sheet
Debt/Equity—
Current Ratio5.14
Quick Ratio2.57
Book Value/Sh1.19 USD
Cash/Share0.50 USD
Dividends
Fwd Div Rate0.16 USD
Trail. Div Rate0.16 USD
Div. Yield1.31%
5Y Avg Yield1.17%
Payout Ratio42.38%
Ex-Div DateMay 8, 2026
Pay Date—
Splits
Last Split5:1
Split DateMay 18, 2022
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)14.96 USD
Upside (mean)+20.8%
Target Range13.78 USD – 16.24 USD
13.78+20.8% to mean16.24
# Analysts3
Ownership
Shares Out.98.50M
Float83.94M
Insiders17.00%
Institutions51.75%
Technical
SMA 5011.65 (+6.3%)
SMA 20011.57 (+7.1%)
Beta0.23
S&P 52W Chg12.00%
Avg Vol (30d)176.76K
Avg Vol (10d)119.89K
Technical Indicators
RSI (14)60.3
MACD1.7708
MACD Signal1.7246
MACD Hist.+0.0462
BB Upper12.67 USD
BB Middle12.15 USD
BB Lower11.62 USD
BB Width8.65%
ATR (14)0.2566 USD
Vol Ratio (20d)0.40x

About BioGaia (STO: BIOG-B)

›

BioGaia (STO: BIOG-B) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 251 employees.

The shares were at 125.80 SEK on 19 November 2026, up 29.8% over 52 weeks. Its 52-week range is 96.20 SEK to 136.30 SEK: the price is 7.7% below the high and 30.8% above the low.

At a market capitalisation of 12.73B SEK, it trades at 32.5 times trailing earnings and 29.1 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.7, a premium of 32% for BIOG-B. It pays a dividend yielding 1.31% (it pays out 42% of its earnings), against a median of 1.90% among the dividend payers in that peer group.

BioGaia reports return on equity of 25.3%, an operating margin of 28.2% and revenue up 22.6% year over year.

It holds more cash than debt, a net cash position of 518.28M SEK. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 3 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 152.00 SEK is 20.8% above the current price. The next earnings report is expected on 12 February 2027.